USP Announces Corrections to General Chapter <1132.1> on Residual Host Cell Protein Measurement
Recommendation

Monday, 21 September 2026 14.00 - 16.00 h
Regulatory Landscape: ECHA, USP, Pharmacopoeias and FDA Enforcement
The United States Pharmacopeia (USP) has announced minor corrections to General Chapter <1132.1> Residual Host Cell Protein Measurement in Biopharmaceuticals by Mass Spectrometry. The chapter was originally published in Pharmacopeial Forum 49(3) and subsequently approved for publication on 01 November 2024, in USP-NF 2025, Issue 1.
The following errata were published on 31 January 2025, and all changes will take effect on 01 May 2025:
- Section 1. INTRODUCTION AND SCOPE – In paragraph 3: Change Residual HCP ELISA to: HCP ELISA.
- Section 4. SAMPLE PREPARATION, CHROMATOGRAPHIC SEPARATION, AND MASS SPECTROMETRY ANALYSIS – In paragraph 4 in 4.1 Sample Preparation: Change product (or polysorbate) to: product protein (or polysorbate).
- Section 5. QUANTITATION OF HCPS – In three instances in 5.1 Methods for HCP Quantitation: Change product to: product protein.
- Section 7. BEST PRACTICES FOR REPORTING DATA FROM ELISA VERSUS LC-MS/MS – In paragraph 1 in 7.3 Comparison of ELISA and LC-MS/MS HCP Results: Change the comparing to: comparing.
For a comprehensive list of errata, refer to the USP-NF Errata Table.
Additionally, please see the Notice of Intent to Revise, published on 01 November 2024, for further details.
Related GMP News
03.09.2026USP Article: Supporting the Detection of Asbestos in Pharmaceutical Talc
02.09.2026USP Publishes Comments Received on Chapter <320>
26.08.2026New USP Requirements for Asbestos Testing in Pharmaceutical Talc
19.08.2026FDA Warning Letter: Averaging Data to Override OOS Findings
12.08.2026ECA's Analytical Control Group Publishes Detailed Report on OOS Survey
12.08.2026BP Publishes Key Insights on Limits in Chromatographic Tests


